These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37302343)

  • 1. Designing the 5HT
    Chauhan A; Singh J; Sangwan N; Singh H; Prakash A; Medhi B; Avti PK
    Epilepsy Res; 2023 Aug; 194():107168. PubMed ID: 37302343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosteric modulation of conserved motifs and helices in 5HT
    Chauhan A; Sangwan N; Singh J; Prakash A; Medhi B; Avti PK
    J Biomol Struct Dyn; 2023; 41(22):13113-13126. PubMed ID: 36809314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Atomic Level Investigation of Sodium Ions Regulating Agonist and Antagonist Binding in the Active Site of a Novel Target 5HT
    Chauhan A; Singh J; Sangwan N; Dhawan R; Avti PK
    Cell Biochem Biophys; 2023 Jun; 81(2):253-267. PubMed ID: 37266904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic insights into sodium ion-mediated ligand binding affinity and modulation of 5-HT2B GPCR activity: implications for drug discovery and development.
    Chauhan A; Singh J; Sangwan N; Avti PK
    J Recept Signal Transduct Res; 2024 Feb; 44(1):8-18. PubMed ID: 38529713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Target-based drug repurposing against Candida albicans-A computational modeling, docking, and molecular dynamic simulations study.
    Verma R; Pradhan D; Nayek A; Singh H; Jain AK; Khan LA
    J Cell Biochem; 2022 Feb; 123(2):289-305. PubMed ID: 34672012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Silico Drug Repurposing Approach: Investigation of
    Ngidi NTP; Machaba KE; Mhlongo NN
    Molecules; 2022 Jan; 27(3):. PubMed ID: 35163931
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug targeted virtual screening and molecular dynamics of LipU protein of Mycobacterium tuberculosis and Mycobacterium leprae.
    Kaur G; Pandey B; Kumar A; Garewal N; Grover A; Kaur J
    J Biomol Struct Dyn; 2019 Mar; 37(5):1254-1269. PubMed ID: 29557724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes.
    Sharif NA; McLaughlin MA; Kelly CR; Katoli P; Drace C; Husain S; Crosson C; Toris C; Zhan GL; Camras C
    Exp Eye Res; 2009 Mar; 88(3):386-97. PubMed ID: 18992242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure investigation, enrichment analysis and structure-based repurposing of FDA-approved drugs as inhibitors of BET-BRD4.
    Wakchaure P; Velayutham R; Roy KK
    J Biomol Struct Dyn; 2019 Aug; 37(12):3048-3057. PubMed ID: 30079805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug repurposing against the RNA-dependent RNA polymerase domain of dengue serotype 3 by virtual screening and molecular dynamics simulations.
    Gangopadhyay A; Saha A
    J Biomol Struct Dyn; 2023 Jul; 41(11):5152-5165. PubMed ID: 35642087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospect of Anterior Gradient 2 homodimer inhibition via repurposing FDA-approved drugs using structure-based virtual screening.
    Ullah S; Khan SU; Khan A; Junaid M; Rafiq H; Htar TT; Zhao Y; Shah SAA; Wadood A
    Mol Divers; 2022 Jun; 26(3):1399-1409. PubMed ID: 34181147
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Ibrahim MAA; Abdelrahman AHM; Hegazy MF
    J Biomol Struct Dyn; 2021 Sep; 39(15):5756-5767. PubMed ID: 32684114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposing of FDA-approved drugs against active site and potential allosteric drug-binding sites of COVID-19 main protease.
    Yuce M; Cicek E; Inan T; Dag AB; Kurkcuoglu O; Sungur FA
    Proteins; 2021 Nov; 89(11):1425-1441. PubMed ID: 34169568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Silico Drug Repurposing of FDA-Approved Drugs Highlighting Promacta as a Potential Inhibitor of H7N9 Influenza Virus.
    Mtambo SE; Kumalo HM
    Molecules; 2022 Jul; 27(14):. PubMed ID: 35889388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting SARS-CoV-2 non-structural protein 13 via helicase-inhibitor-repurposing and non-structural protein 16 through pharmacophore-based screening.
    Samdani MN; Morshed N; Reza R; Asaduzzaman M; Islam ABMMK
    Mol Divers; 2023 Jun; 27(3):1067-1085. PubMed ID: 35690957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repurposing of FDA-approved drugs to target MurB and MurE enzymes in
    Rani J; Silla Y; Borah K; Ramachandran S; Bajpai U
    J Biomol Struct Dyn; 2020 Jun; 38(9):2521-2532. PubMed ID: 31244382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The bulky N6 substituent of cabergoline is responsible for agonism of this drug at 5-hydroxytryptamine 5-HT2A and 5-HT2B receptors and thus is a determinant of valvular heart disease.
    Kekewska A; Hübner H; Gmeiner P; Pertz HH
    J Pharmacol Exp Ther; 2011 Jul; 338(1):381-91. PubMed ID: 21518772
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Maurya AK; Mishra N
    J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 M
    Bharadwaj S; Azhar EI; Kamal MA; Bajrai LH; Dubey A; Jha K; Yadava U; Kang SG; Dwivedi VD
    J Biomol Struct Dyn; 2022 Apr; 40(6):2769-2784. PubMed ID: 33150855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.